Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger S McIntyre

Showing results (31-40 of 1,214) with videos related to

Pageof 122
Sort By:
The Journal of Clinical Psychiatry|July 3, 2009
Introduction: Balancing the equation: managing comorbidities in patients with severe mental illnessRoger S McIntyre
The Journal of Clinical Psychiatry|October 28, 2010
When should you move beyond first-line therapy for depression?Roger S McIntyre
The Journal of Clinical Psychiatry|June 5, 2026
Prescribing GLP-1 Receptor Agonists for Persons With Mental Disorders: Evidence-Based and Aspirational TargetsRoger S McIntyre
The Journal of Clinical Psychiatry|March 14, 2019
Getting to Remission: Differentiating Residual Symptoms From Treatment Side Effects in Major Depressive DisorderRoger S McIntyre
Expert Opinion on Pharmacotherapy|January 21, 2026
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, Major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortalityRoger S McIntyre
Expert Opinion on Drug Safety|April 12, 2025
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?Roger S McIntyre
Expert Opinion on Investigational Drugs|June 18, 2025
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?Roger S McIntyre
Expert Opinion on Drug Safety|July 12, 2022
Rapid-acting antidepressants in psychiatry: episodic treatments, innovation, and clarion call for methodologic rigor in drug developmentRoger S McIntyre
CNS Neuroscience & Therapeutics|October 19, 2010
Asenapine: a review of acute and extension phase data in bipolar disorderRoger S McIntyre
Expert Opinion on Drug Safety|December 17, 2010
Transforming drug safety informationRoger S McIntyre
Pageof 122

Showing results (31-40 of 1,214) with videos related to

Sort By:
Pageof 122
The Journal of Clinical Psychiatry|July 3, 2009
Introduction: Balancing the equation: managing comorbidities in patients with severe mental illnessRoger S McIntyre
The Journal of Clinical Psychiatry|October 28, 2010
When should you move beyond first-line therapy for depression?Roger S McIntyre
The Journal of Clinical Psychiatry|June 5, 2026
Prescribing GLP-1 Receptor Agonists for Persons With Mental Disorders: Evidence-Based and Aspirational TargetsRoger S McIntyre
The Journal of Clinical Psychiatry|March 14, 2019
Getting to Remission: Differentiating Residual Symptoms From Treatment Side Effects in Major Depressive DisorderRoger S McIntyre
Expert Opinion on Pharmacotherapy|January 21, 2026
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, Major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortalityRoger S McIntyre
Expert Opinion on Drug Safety|April 12, 2025
Does the use of generative AI chatbots by patients introduce risk of adverse drug events?Roger S McIntyre
Expert Opinion on Investigational Drugs|June 18, 2025
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?Roger S McIntyre
Expert Opinion on Drug Safety|July 12, 2022
Rapid-acting antidepressants in psychiatry: episodic treatments, innovation, and clarion call for methodologic rigor in drug developmentRoger S McIntyre
CNS Neuroscience & Therapeutics|October 19, 2010
Asenapine: a review of acute and extension phase data in bipolar disorderRoger S McIntyre
Expert Opinion on Drug Safety|December 17, 2010
Transforming drug safety informationRoger S McIntyre
Pageof 122